Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

Related Experiment Video

Updated: Jun 10, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Peripheral T-cell lymphoma--not otherwise specified.

Kerry J Savage1, Andrés J M Ferreri, Pier Luigi Zinzani

  • 1Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.

Critical Reviews in Oncology/Hematology
|August 13, 2010
PubMed
Summary
This summary is machine-generated.

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a rare, aggressive lymphoma with poor prognosis. Current treatments offer limited survival benefits, necessitating research into novel therapeutic strategies for this challenging hematologic malignancy.

More Related Videos

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jun 10, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of mature T-cell lymphomas.
  • It accounts for approximately 25% of all PTCL and over 15% of lymphomas, with low prevalence in Western countries.
  • PTCL-NOS typically presents in adults with disseminated disease, B symptoms, and a high International Prognostic Index (IPI) score.

Purpose of the Study:

  • To summarize the clinicopathological features, prognostic factors, and treatment strategies for PTCL-NOS.
  • To highlight the poor prognosis associated with PTCL-NOS and the need for improved therapeutic approaches.

Main Methods:

  • Review of existing literature on PTCL-NOS, including morphology, immunophenotype, and genetic rearrangements.
  • Analysis of prognostic indicators such as the IPI score and emerging biomarkers.
  • Evaluation of current treatment modalities, including chemotherapy, radiotherapy, and stem cell transplantation (SCT).

Main Results:

  • PTCL-NOS exhibits aberrant T-cell phenotypes (frequent loss of CD5 and CD7) and a high Ki-67 proliferation rate.
  • The IPI score and its variant PIT are the most effective prognostic factors, with a 5-year overall survival of 20-30% for standard treatment.
  • High-dose chemotherapy with SCT shows improved survival rates (40% at 4 years), with graft-versus-lymphoma effects observed in allogeneic SCT.

Conclusions:

  • PTCL-NOS is an aggressive lymphoma with a dismal prognosis, underscoring the need for novel therapeutic agents and strategies.
  • Ongoing clinical trials are investigating new agents like gemcitabine, alemtuzumab, and pralatrexate to improve patient outcomes.
  • Optimizing treatment strategies, including exploring reduced-intensity conditioning for allogeneic SCT, is crucial for managing this disease.